MacroGenics Expands Lorigerlimab Trial After Interim Gynecologic Cancer Results; Stock Down
MacroGenics (MGNX) reported interim Phase 2 results for lorigerlimab in advanced clear cell gynecologic cancer, showing a 25% response rate. The company is expanding the trial, with updated data expected in 2027. MGNX stock fell 38.02% to $2.25 on Friday and was down 7.69% in pre-market trading.
How this was made
The 30-second read
Why it matters
The data provide the first public efficacy readout, influencing investor sentiment and likely driving short-term price pressure.
Market read
First disclosure of trial results for a micro‑cap biotech; immediate stock reaction and potential sector ripple.
What to watch
The trial expansion adds patients, which could improve response metrics in subsequent updates.
Background
MacroGenics presented interim data from its LINNET Phase 2 study at the 2026 ESMO Congress, highlighting efficacy and safety outcomes for lorigerlimab in advanced gynecologic cancers.
Ticker impact
Interim Phase 2 data showed lorigerlimab achieved a 25% objective response rate in advanced clear cell gynecologic cancer with safety concerns, prompting a 38% stock drop.
likely further downside as investors reassess the drug's potential and safety profile
Phase 2 interim results are the first public disclosure; the response rate is modest and Grade 3+ adverse events are high, which typically dampens biotech valuations.
Market effects
May temper enthusiasm for bispecific antibodies in gynecologic oncology and could affect peer biotech valuations.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond the niche oncology sector.
Counterpoint
If later data show durable responses and manageable safety, the stock could rebound on upside potential.
Key entities
- CompanyMacroGenics
Biotech firm developing lorigerlimab, ticker MGNX.
